Literature DB >> 8215874

Definitive surgery for breast cancer performed on an outpatient basis.

A A Goodman1, A L Mendez.   

Abstract

OBJECTIVE: More than 160,000 women will develop breast cancer in the United States during the next year. Traditionally, their definitive surgery has been performed on an inpatient basis, with postoperative hospital stays ranging from 1 to 7 days.
DESIGN: Retrospective review of cases and results. PATIENTS: Two hundred twenty-one patients underwent 223 definitive surgical procedures for carcinoma of the breast, entirely on an outpatient basis, between September 1990 and June 1992. Operations included 31 modified radical mastectomies, 101 partial mastectomies with radical axillary node dissections, 11 total mastectomies, 69 partial mastectomies, and 11 radical axillary dissections.
RESULTS: There were no deaths, and no serious complications. No patient required hospitalization for any reason. There were no wound infections. Patient satisfaction was high, and compliance was excellent.
CONCLUSIONS: Most operations for carcinoma of the breast can be performed on an outpatient basis, without increasing the risk of complications.

Entities:  

Mesh:

Year:  1993        PMID: 8215874     DOI: 10.1001/archsurg.1993.01420220069009

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  9 in total

1.  Implementation of an ultra-short-stay program after breast cancer surgery in four hospitals: perceived barriers and facilitators.

Authors:  Mascha de Kok; Trudy van der Weijden; Alfons Kessels; Carmen Dirksen; Cornelis van de Velde; Jan Roukema; Fred van der Ent; Antoine Bell; Maarten von Meyenfeldt
Journal:  World J Surg       Date:  2008-12       Impact factor: 3.352

2.  Medical and psychosocial effects of early discharge after surgery for breast cancer: randomised trial.

Authors:  J Bonnema; A M van Wersch; A N van Geel; J F Pruyn; P I Schmitz; M A Paul; T Wiggers
Journal:  BMJ       Date:  1998-04-25

3.  Factors Affecting the Postsurgical Length of Hospital Stay in Patients with Breast Cancer.

Authors:  Metehan Gümüş; Ömer Satıcı; Burak Veli Ülger; Abdullah Oğuz; Fatih Taşkesen; Sadullah Girgin
Journal:  J Breast Health       Date:  2015-07-01

4.  Hospital-Based Same-Day Compared to Overnight-Stay Mastectomy: An American College of Surgeons National Surgical Quality Improvement Program Analysis.

Authors:  Udai S Sibia; John R Klune; Justin J Turcotte; Luther H Holton; Adam I Riker
Journal:  Ochsner J       Date:  2022

5.  Seroma formation after breast cancer surgery: what we have learned in the last two decades.

Authors:  Vivek Srivastava; Somprakas Basu; Vijay Kumar Shukla
Journal:  J Breast Cancer       Date:  2012-12-31       Impact factor: 3.588

6.  Introduction of a breast cancer care programme including ultra short hospital stay in 4 early adopter centres: framework for an implementation study.

Authors:  Mascha de Kok; Caroline N A Frotscher; Trudy van der Weijden; Alfons G H Kessels; Carmen D Dirksen; Cornelis J H van de Velde; Jan A Roukema; Antoine V R J Bell; Fred W van der Ent; Maarten F von Meyenfeldt
Journal:  BMC Cancer       Date:  2007-07-02       Impact factor: 4.430

7.  Adopting ambulatory breast cancer surgery as the standard of care in an asian population.

Authors:  Yvonne Ying Ru Ng; Patrick Mun Yew Chan; Juliana Jia Chuan Chen; Melanie Dee Wern Seah; Christine Teo; Ern Yu Tan
Journal:  Int J Breast Cancer       Date:  2014-08-12

8.  Comparative study to assess the quality of analgesia of bupivacaine and bupivacaine with dexmedetomidine in ultrasound-guided pectoral nerve block type I and II in breast surgeries.

Authors:  Shaiqa Manzoor; Rajeev Taneja; Nishant Sood; Arun Puri; Geeta Kadayaprath
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2018 Apr-Jun

9.  Outpatient Mastectomy: Factors Influencing Patient Selection and Predictors of Return to Care.

Authors:  Brooke Vuong; Jennifer R Dusendang; Sharon B Chang; Margaret Ann Mentakis; Veronica C Shim; Julie Schmittdiel; Gillian Kuehner
Journal:  J Am Coll Surg       Date:  2020-10-03       Impact factor: 6.113

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.